Pelthos Therapeutics Inc. cotiza a 19.52 USD y tiene una capitalización bursátil de $75M. En los últimos 12 meses ha facturado $43M con un margen de flujo de caja libre del -135.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrob…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-4.66 | $-2.69 |
| Estimado | $-3.06 | $-2.95 | $-3.58 | $-4.18 |
| Sorpresa | — | — | -30.2% | +35.6% |
| Métrica | PTHS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 76.3% | 57.0% | +19.2% |
| Operating Margin | -193.1% | -38.6% | -154.5% |
| Net Margin | -257.9% | -33.6% | -224.4% |
| FCF Margin | -135.1% | -13.9% | -121.2% |
| ROE | -111.4% | -40.4% | -71.0% |
| ROA | -33.2% | -32.0% | -1.2% |
| Current Ratio | 2.05 | 2.84 | -0.79 |
| Debt / Equity | — | 0.28 | — |